Tumor necrosis factor-α and interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB

Micaela Morgado, Margie N. Sutton, Mary Simmons, Curtis R. Warren, Zhen Lü, Pamela E. Constantinou, Jinsong Liu, Lewis W. Francis, R. Steven Conlan, Robert C. Bast,

Oncotarget · 2016 · 64 citations · 39 references

DOIFull text

Open access

Concepts

Abstract

// Micaela Morgado 1 , Margie N. Sutton 2, 3 , Mary Simmons 2 , Curtis R. Warren 4 , Zhen Lu 2 , Pamela E. Constantinou 1 , Jinsong Liu 5 , Lewis LW. Francis 7 , R. Steven Conlan 7 , Robert C. Bast Jr 2 , Daniel D. Carson 1, 6 1 Department of BioSciences, Wiess School of Natural Sciences, Rice University, Houston, TX 77251, USA 2 Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 3 The University of Texas Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA 4 Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA 5 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA 6 Department of Genetics, The University of Texas MD Anderson Cancer Center Houston, TX 77030, USA 7 Swansea University Medical School, Singleton Park, Swansea, SA2 8PP, Wales, UK Correspondence to: Daniel D. Carson, e-mail: dcarson@rice.edu Keywords: MUC16, CA125, cytokine, NFκB, cancer Received: July 23, 2015      Accepted: January 31, 2016      Published: February 24, 2016 ABSTRACT Transmembrane mucins (TMs) are restricted to the apical surface of normal epithelia. In cancer, TMs not only are over-expressed, but also lose polarized distribution. MUC16/CA125 is a high molecular weight TM carrying the CA125 epitope, a well-known molecular marker for human cancers. MUC16 mRNA and protein expression was mildly stimulated by low concentrations of TNFα (2.5 ng/ml) or IFNγ (20 IU/ml) when used alone; however, combined treatment with both cytokines resulted in a moderate (3-fold or less) to large (> 10-fold) stimulation of MUC16 mRNA and protein expression in a variety of cancer cell types indicating that this may be a general response. Human cancer tissue microarray analysis indicated that MUC16 expression directly correlates with TNFα and IFNγ staining intensities in certain cancers. We show that NFκB is an important mediator of cytokine stimulation of MUC16 since siRNA-mediated knockdown of NFκB/p65 greatly reduced cytokine responsiveness. Finally, we demonstrate that the 250 bp proximal promoter region of MUC16 contains an NFκB binding site that accounts for a large portion of the TNFα response. Developing methods to manipulate MUC16 expression could provide new approaches to treating cancers whose growth or metastasis is characterized by elevated levels of TMs, including MUC16.

References

39